Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 12 (December)

1. Inhibition of phosphatidylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells.
   Clin Cancer Res, 11(23): 8521-7. [Abstract] [Full-text]
2. The use of genetic markers to determine risk for prostate cancer at prostate biopsy.
   Clin Cancer Res, 11(23): 8391-7. [Abstract] [Full-text]
3. Elevated expression of angiogenin in prostate cancer and its precursors.
   Clin Cancer Res, 11(23): 8358-63. [Abstract] [Full-text]
4. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
   Clin Cancer Res, 11(23): 8321-5. [Abstract] [Full-text]
5. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer.
   Clin Cancer Res, 11(23): 8295-303. [Abstract] [Full-text]
6. Management of gynaecomastia in patients with prostate cancer: a systematic review.
   Lancet Oncol, 6(12): 972-9. [Abstract] [Full-text]
7. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells.
   Int J Cancer, 118(3): 609-15. [Abstract] [Full-text]
8. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
   Oncology, 69(4): 273-82. [Abstract] [Full-text]
9. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
   J Clin Endocrinol Metab, 90(12): 6410-7. [Abstract] [Full-text]
10. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis.
    J Natl Cancer Inst, 97(23): 1768-77. [Abstract] [Full-text]
11. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
    Exp Cell Res, 312(2): 184-97. [Abstract] [Full-text]
12. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes.
    Nat Rev Cancer, 5(12): 977-85. [Abstract] [Full-text]
13. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    BJU Int, 97(1): 170-8. [Abstract] [Full-text]
14. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    BJU Int, 97(1): 62-8. [Abstract] [Full-text]
15. Treatment of localized prostate cancer using high-intensity focused ultrasound.
    BJU Int, 97(1): 56-61. [Abstract] [Full-text]
16. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    BJU Int, 97(1): 51-5. [Abstract] [Full-text]
17. Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?
    BJU Int, 97(1): 48-50. [Abstract] [Full-text]
18. A population-based study of renal cell carcinoma and prostate cancer in the same patients.
    BJU Int, 97(1): 33-6. [Abstract] [Full-text]
19. Hope springs eternal: cavernosal nerve regeneration.
    BJU Int, 97(1): 17-21. [Abstract] [Full-text]
20. Polymeric nanoparticle preparation that eradicates tumors.
    Nano Lett, 5(12): 2552-6. [Abstract] [Full-text]
21. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma.
    Cancer, 104(12): 2689-700. [Abstract] [Full-text]
22. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project.
    Prostate, 66(2): 173-9. [Abstract] [Full-text]
23. N-cadherin switching occurs in high Gleason grade prostate cancer.
    Prostate, 66(2): 193-9. [Abstract] [Full-text]
24. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Prostate, 66(2): 200-10. [Abstract] [Full-text]
25. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.
    Prostate, 66(2): 218-25. [Abstract] [Full-text]
26. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.
    Prostate, 66(2): 146-56. [Abstract] [Full-text]
27. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Prostate, 66(2): 180-92. [Abstract] [Full-text]
28. Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
    Prostate, 66(2): 211-7. [Abstract] [Full-text]
29. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer.
    Prostate, 66(2): 157-72. [Abstract] [Full-text]
30. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    Prostate, 66(2): 124-34. [Abstract] [Full-text]
31. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.
    Prostate, 66(2): 135-45. [Abstract] [Full-text]
32. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.
    Clin Cancer Res, 11(24): 8680-5. [Abstract] [Full-text]
33. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
    Clin Cancer Res, 11(24): 8669-73. [Abstract] [Full-text]
34. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions.
    Radiology, 238(1): 192-9. [Abstract] [Full-text]
35. Endorectal MR imaging before salvage prostatectomy: tumor localization and staging.
    Radiology, 238(1): 176-83. [Abstract] [Full-text]
36. Prostate cancer: local staging at 3-T endorectal MR imaging--early experience.
    Radiology, 238(1): 184-91. [Abstract] [Full-text]
37. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.
    Int J Cancer, 118(5): 1108-19. [Abstract] [Full-text]
38. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Int J Cancer, 118(5): 1234-40. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.